Sonne H S, Larsen B, Asfeldt V H
Medicinsk afdeling, Herning Centralsygehus.
Ugeskr Laeger. 1993 Oct 25;155(43):3483-6.
The aim of this study was to assess the results of 131-I therapy on hyperthyroidism. 131-I doses were individually calculated on the basis of thyroid gland classification, size and iodine-uptake. All patients were pretreated with propylthiouracil or methimazole. Seventy-nine patients treated with radio-iodine during the period 1.3.81-1.6.88 were followed up. The period of observation was 12-100 months (median 57). After eight years and four months the cumulative incidence of hypothyroidism was 45%, being 69% for diffuse goitre, 31% for multinodular goitre and 24% for solitary adenoma. A Cox-analysis showed a significantly greater cumulative incidence of hypothyroidism in patients with diffuse goitre as opposed to non-diffuse. From our data we conclude that radio-iodine therapy of hyperthyroidism with individually calculated doses of 131-I is a satisfactory method, assuming that patients are subjected to lifelong follow-up.
本研究的目的是评估¹³¹碘治疗甲状腺功能亢进症的效果。¹³¹碘剂量根据甲状腺分类、大小和碘摄取量单独计算。所有患者均先用丙硫氧嘧啶或甲巯咪唑进行预处理。对1981年3月1日至1988年6月1日期间接受放射性碘治疗的79例患者进行了随访。观察期为12至100个月（中位数为57个月）。8年零4个月后，甲状腺功能减退症的累积发病率为45%，弥漫性甲状腺肿患者为69%，多结节性甲状腺肿患者为31%，孤立性腺瘤患者为24%。Cox分析显示，与非弥漫性甲状腺肿患者相比，弥漫性甲状腺肿患者甲状腺功能减退症的累积发病率显著更高。根据我们的数据，我们得出结论，假设患者接受终身随访，采用单独计算剂量的¹³¹碘治疗甲状腺功能亢进症是一种令人满意的方法。
